$NGVT

Li David H sold $765K of NGVT

Li David H (President & CEO) sold 10,092 shares of Ingevity Corp (NGVT) at an average of $75.77 ($74.71–$75.83, $0.76M total) across 3 trades over 2026-08-14 to 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Li David H
Published Aug 18, 2026, 9:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 10:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NGVT
Neutral
medium confidence
Mentioned
$NGVT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NGVTNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider confidence, but the disclosure does not provide new fundamentals or forward-looking guidance.

02

Market read

A scheduled insider sale of about $765K in NGVT shares was reported, with no other company-specific news included.

03

What to watch

Insider sales can be driven by diversification, taxes, or scheduled liquidity needs; without changes to other insiders or new company disclosures, the trading edge is limited.

Relevance 4/10Novelty 4/10Timing: filed Aug 18, after-hours (SEC Form 4)

Background

The article is an SEC Form 4 insider transaction disclosure for Ingevity (NGVT) by its President and CEO under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$NGVTNeutralMedium confidence
Context

Ingevity CEO Li David H sold $764,673 of NGVT shares via a 10b5-1 plan across three trades from Aug 14 to Aug 18.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst from the filing alone.

Evidence & confidence

The filing is a routine Form 4 open-market sale under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or operational change disclosed.

Market effects

Minimal, as this is company-specific insider selling with no sector-wide regulatory or demand signal.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can still coincide with private information, but the pre-arranged nature reduces the signal strength.

Key entities

  • Ingevity Corp

    Subject of the Form 4 insider transaction disclosure.

  • Li David H

    President and CEO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NGVTMedAI 8/10

Ingevity (NGVT) Q2 2026 Earnings Call Transcript

Ingevity (NGVT) held its Q2 2026 earnings call. Net sales were $314 million, down 5% on reported basis due to the Road Markings divestiture. Adjusted EBITDA rose 14% to $115 million, with margin at 36.6%. Adjusted EPS was $1.74. Free cash flow was $89 million. Full-year guidance for EBITDA and EPS was raised.

$NGVTMedAI 8/10

Ingevity Q2 Earnings Call Highlights

Ingevity (NYSE:NGVT) reported Q2 cash flow excluding a litigation settlement of about $89M, or $2.52/share, with capex near $10M. Performance Materials sales rose 4% to $161M, with segment EBITDA up 6% to $86M and margin to 53.6%. The company raised 2026 outlook to adjusted EBITDA $380M-$400M and EPS $5.00-$5.45, plus free cash flow $220M-$245M.

$NGVTMed

Ingevity Corp (NGVT): Results of Operations and Financial Condition

Ingevity Corp (NGVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Ingevity reports second quarter 2026 financial results Second Quarter 2026 Results and Recent Highlights: • Net sales of $314.1 million decreased 5% from prior year; exc